Gilead Sciences | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Agios Pharmaceuticals USD 7.64M 1.83M 2025-03
ALKERMES USD 257.31M 110.81M 2025-03
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Amgen USD 5.54B 430M 2025-03
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Eli Lilly USD 10.5B 624.7M 2025-03
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.59B 34M 2025-03
Glaxosmithkline GBP 5.6B 94M 2024-12
Incyte USD 985.09M 111.22M 2025-03
J&J USD 14.6B 816M 2025-03
Merck USD 12.77B 849M 2025-03
Moderna USD 17M 403M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Pfizer USD 11.12B 987M 2025-03
PTC Therapeutics USD 196.89M 10.95M 2024-12
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Sanofi EUR 7.72B 2.36B 2025-03
Sarepta Therapeutics USD 607.29M 81.18M 2025-03
United Therapeutics USD 701.9M 41.9M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12



Gilead Sciences Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.